The fetal epidermal barrier undergoes rapid development during late gestation despite conditions injurious to the skin postnatally, i.e. prolonged exposure to water (urine) and noxious substances such as pancreatic chymotrypsin. Nevertheless, at birth, term newborns have a superb epidermal barrier. Concomitant with formation of the stratum corneum in utero, vernix caseosa forms a natural multifunctional cream separating the skin surface from the amniotic fluid with possible unique barrier properties. Therefore, we investigated the effect of native vernix, synthetic vernix, and Desitin ® on penetration of chymotrypsin, a proteolytic enzyme present in both developing epidermis and meconium. ␣-Chymotrypsin penetration through test materials was conducted in vitro using a modified Franz diffusion cell. The presence of ␣-chymotrypsin in vernix and a possible inhibitory effect of vernix on ␣-chymotrypsin activity were investigated. Vernix films significantly impeded chymotrypsin penetration compared with controls during 24-h exposure experiments. ␣-Chymotryptic activity in vernix was undetectable, and vernix showed no endogenous inhibition of such activity. Both synthetic vernix and Desitin ® significantly impeded ␣-chymotrypsin penetration compared with controls during 9-h exposure experiments. With respect to the developing epidermal barrier, these results are consistent with the hypothesis that vernix films retain endogenous (epidermal) chymotrypsin while preventing exposure to exogenous (pancreatic) chymotrypsin. T he intrauterine development of the human skin barrier as an interface between the internal and external environment is critical for postnatal survival of the organism. One of the most striking changes during late gestation of pregnancy is the presence of vernix caseosa on the fetal skin surface. Vernix is a viscous, whitish, pastelike material that overlies the fetal stratum corneum (1). By composition, vernix is mainly composed of water (80%), lipid (10.3%), and protein (9.1%) (2). It consists of a lipid matrix containing detached corneocytes derived from possible remnants of the epitrichium, the differentiating fetal epidermis, and the pilosebaceous unit (3,4). Vernix lipid is, thus, composed of two types of lipid: sebaceous lipid and stratum corneum lipid (5-8). The continuous (nonlamellar) phase of vernix lipid surrounding the cellular components has a low surface energy and results in a highly unwettable material located at the fetal skin surface (9). This interfacial hydrophobic material has been investigated as a defense against infection both pre-and postnatally with beneficial physicochemical properties providing barrier protection and facilitating development of the acid mantle (10 -12).
T he intrauterine development of the human skin barrier as an interface between the internal and external environment is critical for postnatal survival of the organism. One of the most striking changes during late gestation of pregnancy is the presence of vernix caseosa on the fetal skin surface. Vernix is a viscous, whitish, pastelike material that overlies the fetal stratum corneum (1) . By composition, vernix is mainly composed of water (80%), lipid (10.3%), and protein (9.1%) (2) . It consists of a lipid matrix containing detached corneocytes derived from possible remnants of the epitrichium, the differentiating fetal epidermis, and the pilosebaceous unit (3, 4) . Vernix lipid is, thus, composed of two types of lipid: sebaceous lipid and stratum corneum lipid (5) (6) (7) (8) . The continuous (nonlamellar) phase of vernix lipid surrounding the cellular components has a low surface energy and results in a highly unwettable material located at the fetal skin surface (9) . This interfacial hydrophobic material has been investigated as a defense against infection both pre-and postnatally with beneficial physicochemical properties providing barrier protection and facilitating development of the acid mantle (10 -12) .
Paradoxically, the fetal skin barrier undergoes rapid development during late gestation under conditions of total immersion in amniotic fluid. In vitro, skin culturists must raise human skin to an air interface to promote barrier development (13, 14) . This raises the biologic question of how the human fetus accomplishes this feat in utero. Amniotic fluid is a complex mixture of many bioactive constituents including electrolytes, lipids, amino acids, growth factors, cytokines, and enzymes (15, 16) . The presence of an unexpectedly high concentration of chymotrypsin in amniotic fluid has been reported as early as wk 18 of gestation (17) . The source of this material is unknown, and its study could potentially elucidate new interactions in the fetal environment.
Chymotrypsin is a serine protease. Its activity and conformational stability are pH and temperature dependent (18, 19) . Maximal activity of chymotrypsin appears at pH 7-8 in contrast to its physiochemical stability, which is maximal under acidic conditions. The pH of amniotic fluid is approximately 7 (15) . Consequently, the formation of the fetal epidermal barrier in amniotic fluid occurs at the optimum pH for chymotryptic activity. A functionally superb epidermal barrier is developed during late gestation, and superior epidermal barrier properties are detected in term newborn infants (20, 21) . It is interesting to note that epidermal barrier formation coincides with the presence of vernix formation in utero (22) . This finding led us to hypothesize that vernix caseosa facilitates epidermal barrier formation and barrier homeostasis of fetal skin in utero by providing a barrier to impede the loss of biologic enzymes necessary for barrier differentiation and also by preventing the developing skin from incurring damage from noxious agents present in the intrauterine environment (Fig. 1) .
After birth, diaper dermatitis is the most common cutaneous disorder of infancy and early childhood. Stool chymotrypsin, in combination with other enzymes, has been reported to have a high skin irritation potential (23) (24) (25) . The level of irritancy corresponds to enzyme concentration and the pH condition of the test solution. Therefore, fecal enzymes under the diaper are believed to be a primary factor leading to and perpetuating this skin disorder (26) . We also hypothesized that natural endogenous barrier films such as vernix may prevent the penetration of digestive enzymes from stool. Substantiation of this hypothesis supports leaving vernix on infant skin after birth. In a similar manner, vernix may protect the fetal skin from possible deleterious effects of meconium exposure in utero.
In this work, we studied the penetration of chymotrypsin through vernix films as a function of film thickness. The presence of chymotryptic activity in vernix and the possible inhibitory effect of vernix on enzyme activity were also investigated. The barrier properties of a synthetic vernix formulation and a common commercial ointment for treatment of diaper dermatitis were also studied and contrasted to native vernix.
METHODS
Materials. ␣-Chymotrypsin TLCK treated from bovine pancreas, Nbenzoyl-L-tyrosine-ethyl-ester (BTEE), bovine serum albumin (BSA), calcium chloride, sodium azide, and dodecyltrimethylammonium chloride (DTMAC) were purchased from Sigma Chemical Co.-Aldrich (St. Louis, MO). Chymotrypsin was used without further purification. HT-Tuffryn membrane, a hydrophilic polysulfone membrane with a pore size of 0.45 m was purchased from Pall Corporation (Ann Arbor, MI). Desitin ® , a commercial ointment for treating diaper dermatitis, was selected as a common benchmark. Desitin ® consists of zinc oxide, butylated hydroxyanisole, cod liver oil, fragrance, lanolin, methylparaben, petrolatum, talc, and water. It shows a water vapor transport value of 1.8 Ϯ 0.5 g/m 2 /h (27) . A synthetic vernix formulation was prepared in the laboratory as a high internal phase water-inoil emulsion. The emulsion had a high aqueous content (78% weight) with lipid composition of squalene, linoleic acid, cholesterol, ceramide III, cholesterol sulfate, triglyceride, lanolin, and beeswax. The synthetic vernix shows a water release rate and water vapor transport comparable to those of native vernix (27) .
Vernix collection and spreading. Vernix caseosa was collected from full-term infants born at University Hospital, Cincinnati, OH, with institutional review board approval and informed consent. It was immediately transferred into sterile airtight plastic tubes and kept at 4°C until used. Portions of samples contaminated with blood were discarded. All vernix samples were used within a month after collection. Vernix was spread into a uniform film over a HT-Tuffryn membrane using a special mechanical applicator (Accu Gate Fluid Spreader). This metered gate allows the vernix to flow through thereby controlling the film thickness applied. The applicator was held at a 45-degree angle and was drawn smoothly over the vernix to produce a uniform coating in which the thickness of the film obtained depends on the depth of the gate. The film thicknesses produced were 3, 6, or 9 mils or 76.2, 152.3, and 228.6 m, respectively (1 unit mil equals to 25.4 m).
Measurement of chymotrypsin activity. The activity of ␣-chymotrypsin was assayed by continuous spectrophotometric monitoring of the hydrolysis of BTEE described by Hummel (28) . The reaction cocktail contained 1.40 mL of 1.18 mM BTEE prepared in 25% methanol, 1.42 mL of 0.1 M Tris buffer pH 7.85, and 0.08 mL of 2 M calcium chloride. The reaction cocktail was monitored using SmartSpec-3000 Spectrophotometer and equilibrated at 25°C. The enzymatic reactions were initiated by the addition of 0.1 mL enzyme solution and the increase in absorbance at 256 nm was recorded every minute for 5 min. An increase in absorbance per minute (⌬A 256 /min) was obtained from the maximum linear rate. ⌬A 256 /min was converted to amount of chymotrypsin using standard curve generated by ␣-chymotrypsin with a concentration range of 0.4 -30 g/mL (0.031-2.33 U/mL).
Study of enzyme stability. ␣-Chymotrypsin was prepared in 0.1 M of citrate buffer (0.4 mg/mL) with or without the presence of 0.25 mg/mL of BSA. Citrate buffer used was pH 3, 4, 5, and 6, and the buffer was prewarmed at 37°C before an addition of ␣-chymotrypsin. The enzyme solutions were then stored at 37°C in a thermostatic water bath, and an aliquot of the solution was taken at appropriate intervals for the residual activity assay described earlier.
Penetration study of chymotrypsin. To evaluate barrier protective properties, uniform films of vernix and test materials including synthetic vernix and Desitin ® were spread on to HT-Tuffryn membrane using the Accu Gate spreader. Test films were mounted on modified Franz diffusion cells between donor and receptor compartments (Fig. 2) . The receptor compartments were stirred and maintained at 37°C by thermostatted heating-stirring modules. The receptor solution was 0.1 M of citrate buffer at pH 3, containing 0.25 mg/mL of BSA to prevent enzyme adsorption on the glass wall and 0.02% sodium azide to retard microbial growth. The experiment was initiated by addition of ␣-chymotrypsin in pH 3 0.1 M citrate buffer (0.4 mg/mL or 31.1 U/mL) into the donor chamber. Samples of receptor fluid were collected at predetermined time intervals and were replaced with an appropriate volume of buffer. The collected samples were investigated for the presence of ␣-chymotrypsin over time by continuous spectrophotometry. Penetration studies were carried out over a 24-h period. A Franz cell system containing only HT-Tuffryn membranes served as a control.
Presence of ␣-chymotrypsin in vernix. Citrate buffer (pH 3) with either 0.26% or 0.13% DTMAC was selected as an extracting medium. One hundred milligrams of vernix was homogenized in 2 mL of extracting medium using Tissue Tearor homogenizer for at least 1 min. The resulting vernix suspension was centrifuged at 7000 rpm, and the clear supernatant was measured for the presence of ␣-chymotrypsin.
Inhibitory effect of vernix on ␣-chymotrypsin activity. ␣-Chymotrypsin solution was prepared in 0.1 M of citrate buffer pH 3 to yield a concentration of either 1.55 or 31.1 U/mL. Native vernix was added to the chymotrypsin solution (50 mg/mL) and was homogenized for 1 min using a Tissue Tearor homogenizer. The experiment was conducted over ice to minimize enzyme autodegradation. After 2 h, the supernatant was removed for measurement of the remaining enzyme activity compared with control chymotrypsin solutions without the presence of vernix.
RESULTS
Enzyme stability. The effects of pH on the stability of ␣-chymotrypsin activity in citrate buffer are shown in Figure  3 . The results are reported as residual activity of ␣-chymotrypsin with respect to initial enzyme activity in citrate buffer at pH 3, 4, 5, and 6. The activity of ␣-chymotrypsin decreased with increasing buffer pH. ␣-Chymotrypsin in buffer pH 3 at 37°C was stable for at least 24 h; therefore, citrate buffer pH 3 was selected as a medium used in the penetration study. Figure 3b shows the effect of additional protein (BSA) concentration on enzyme stability. The addition of 0.25 mg/mL of BSA did not decrease enzyme stability over 24 h and did not affect spectrophotometric measurement of enzyme activity. Figure 4a shows the total cumulative amount of ␣-chymotrypsin penetration through vernix films of different thickness compared with the control (HT-Tuffryn membrane only). The result demonstrates that vernix, at all film thicknesses, showed a significant effect to prevent penetration of ␣-chymotrypsin compared with the control at all time points up to 24 h. Figure  4b presents the same data focusing on the total cumulative amount of ␣-chymotrypsin penetrating vernix films of different thickness. As shown, the presence of chymotrypsin was barely detectable in the receptor compartment after 1 h at all levels tested. The extent of chymotrypsin penetration was inversely proportional to vernix film thickness, but there was no significant difference among film levels at 24 h due to data scatter. Figure 5a shows ␣-chymotrypsin penetration through similar films of vernix, synthetic vernix, and Desitin ® spread on HT-Tuffryn membrane compared with the control (HTTuffryn membrane). At 6 h, ␣-chymotrypsin penetration through all test films was at least 23-fold lower than that of the HT-Tuffryn membrane control. This result demonstrates that thin films of test materials (3 mils thick) significantly prevented penetration of ␣-chymotrypsin compared with controls throughout the 9-h study. Figure 5b presents the same data focusing on the total cumulative amount of ␣-chymotrypsin penetrating through the test material films. The presence of ␣-chymotrypsin was undetectable until the second hours with vernix and synthetic vernix as the test film membranes. This figure shows higher amounts of ␣-chymotrypsin penetrating through synthetic vernix compared with native vernix. The results, however, were not significantly different due to high variability. ␣-Chymotrypsin penetration through Desitin ® was very low with no detectable enzyme activity at any time point of the experiment.
Penetration of ␣-chymotrypsin through test membranes.
Presence of ␣-chymotrypsin in native vernix. ␣-Chymotrypsin activity was assayed in native vernix samples as shown in Table 1 . Standard curves of ␣-chymotrypsin, generated using buffer containing 0.26% and 0.13% DTMAC, provided detection limits of 0.062 and 0.049 U/mL, respectively. Increasing DTMAC concentrations lowered the sensitivity of the spectrophotometric measurement, thereby affecting measurable ␣-chymotrypsin activity. Clear supernatant, obtained after homogenization of vernix and an extracting medium, containing either 0.26% or 0.13% DTMAC, showed values below the detection limits measured by spectrophotometric determination of absorbance at 256 nm. Therefore, 50 mg of vernix contained less than 0.049 U of ␣-chymotrypsin.
Inhibitory effect of vernix on ␣-chymotrypsin activity. Inhibitory effect of vernix on ␣-chymotrypsin activity was studied in the representative experiment presented in Figure 6 . Residual activity of ␣-chymotrypsin is presented as the percentage of relative activity compared with control. Two hours after homogenization of vernix in either 1.55 or 31.1 U/mL ␣-chymotrypsin, the relative activity of ␣-chymotrypsin compared with control remained at 98.0 Ϯ 2.1% or 99.6 Ϯ 2.4%, respectively. Based on these results, native vernix does not significantly inhibit ␣-chymotrypsin activity.
DISCUSSION
As early as wk 5 of gestation, the embryo is covered by a single-cell epithelium derived from ectoderm. By the end of the second trimester, the major structures of stratified epidermis can be detected, but stratum corneum formation is scant. Vernix caseosa is a viscous, whitish substance coating the fetal skin surface during the last trimester. Morphologically, Agorastos et al. (3) reported a cellular component of vernix, a finding confirmed and extended by our laboratory (4) . Electron micrographs show the presence of fetal corneocytes surrounded by unstructured vernix lipid. The production of vernix coincides with the presence of a terminally differentiated epidermis as evidenced by the formation of the stratum corneum. These findings support a possible role of vernix in 51 the process of barrier formation in in utero; however, the mechanism is not clearly understood. Of interest, other properties of vernix have been investigated showing antimicrobial (10, 11, 29, 30) , moisturizing (31), cleansing (32) , and barrier repair (33) properties.
In the process of terminal differentiation, several metabolic enzymes are required for formation of a competent epidermal barrier. Phospholipase-A 2 , ␤-glucocerebosidase, and stratum corneum chymotryptic enzyme (SCCE) are major enzymes responsible for barrier differentiation and homeostasis. Phospholipase-A 2 and ␤-glucocerebosidase are required for the transformation of phospholipids into free fatty acids (FFAs) and of glycosylceramides into ceramides, respectively. An increase in FFAs and ceramides within the interstices of the stratum corneum leads to formation of intercellular lamellar units, which are critical for the epidermal permeability barrier (34) . SCCE is known to contribute to the cell shedding process by catalyzing the degradation of intercellular cohesive structures, i.e. corneodesmosomes, at the skin surface (35) . This process, known as desquamation, precisely matches the continuous de novo production of the epidermal barrier from the underlying nucleated epidermal cells.
Given the critical role of SCCE in desquamation, loss of this enzyme could lead to corneocyte retention and hyperkeratosis as is commonly seen in certain skin disorders (36) . Overexpression of SCCE may result in deterioration of stratum corneum integrity and cohesion (37). Hachem et al. (37) have shown that an increase in serine protease activity provokes a significant decrease in the density of corneodesmosomes, which can be reversed by a co-application of serine protease inhibitor. Therefore, an imbalance of SCCE by either over-or underexpression may play a significant part in impaired permeability function and skin pathophysiology.
The fetal skin barrier develops during late gestation in a totally aqueous environment. Given the fact that the external surface of the fetal organism directly faces the amniotic fluid, dilution or depletion of enzymes required for barrier development can hypothetically occur (Fig. 1b) . The present study, therefore, focuses on the barrier effect of vernix on the penetration of SCCE. Bovine chymotryptic enzyme was used as a model for human SCCE in the experiments because it has a size, structure, and catalytic activity similar to those of SCCE (38) . The results demonstrate for the first time that vernix functions as a natural barrier to impede penetration of chymotryptic enzymes. Hypothetically, a surface film of vernix in utero, positioned between the fetus and the amniotic fluid, impedes the loss of chymotryptic enzyme (SCCE) from the developing fetal barrier, thereby providing an optimum concentration of enzyme for desquamation. Whether such desquamation occurs prenatally or postnatally is unknown. Vernix itself contains numerous corneocytes (4), but it is not known whether these cells arise from the pilosebaceous unit or the interfollicular epidermis.
In addition to the presence of SCCE within the fetal epidermal barrier, chymotryptic enzymes have been identified in amniotic fluid during mid gestation (17) . The source of chymotrypsin in amniotic fluid is unknown (Fig. 1a) . Pancreatic chymotrypsin is a normal constituent of fetal feces (meconium). Chymotrypsin in combination with other lipolytic and proteolytic enzymes present in meconium has been reported to possess barrier irritation potential in vivo (23, 24, 39) . The degree of irritancy corresponds to the enzyme concentration and the pH of the environment (23) . Low concentrations of proteolytic enzymes under alkaline conditions cause as much skin irritation as high enzymatic concentrations under acidic conditions (23) . Due to the protective property demonstrated in this study, vernix not only potentially prevents the loss of epidermal chymotryptic enzyme required for barrier homeostasis but also protects the nascent fetal barrier from damage caused by potentially harmful chymotryptic enzymes present in amniotic fluid. No inhibitory effect of vernix on chymotryptic activity was detected. The protective barrier properties of vernix, therefore, are due to mechanical obstruction or occlusion. Taken altogether, the results indicate a novel mechanism whereby natural skin creams may regulate fetal barrier homeostasis in utero.
In the extrauterine environment, the ability of vernix to prevent penetration of chymotrypsin may also be beneficial for the infant. Leaving vernix in situ at the time of birth may Results are reported as an increase in absorbance per minute (⌬A/min). After homogenization of vernix with buffer containing DTMAC, supernatant activity was below the detection limit, demonstrating less than 0.049 U of ␣-chymotrypsin in 50 mg of vernix. protect infant skin from exogenous contact with stool chymotrypsin and other noxious agents present in feces or urine. Chymotrypsin, in the presence of alkaline urine within the diaper area, has been reported to be a primary factor causing the skin irritation seen in diaper dermatitis (26) . The protective barrier property of vernix can be closely matched by other nonnatural barrier films. Thus, a formulated synthetic vernix as well as Desitin ® , a commercial ointment for treating diaper dermatitis, partially prevented or completely blocked chymotrypsin penetration, respectively (Fig. 5) . It can be inferred from our results that native vernix, synthetic vernix, and Desitin ® may potentially prevent or alleviate diaper dermatitis or other skin disorders caused by the irritating effect of chymotryptic enzyme. Of note, vernix and its synthetic equivalent are approximately 10 times less occlusive to water vapor transport than commercial lipid ointments, such as Desitin ® (see Materials section). Vernix films provide a water vapor transport in the range reported to facilitate barrier repair (40) . Total occlusion of the skin by vapor impermeable ointments has been shown to increase microbial infection of immature skin and to hinder barrier repair (41) (42) (43) . Because the management and prevention of diaper dermatitis aim to keep the area dry, to prevent long-term contact with urine or fecal enzymes, and to promote barrier repair of damaged skin, therefore, either native vernix or synthetic vernix formulations may have advantages over commercial ointments such as of Desitin ® .
In conclusion, this study shows that thin films of a naturally occurring emollient, vernix caseosa, provide a protective barrier to penetration of potentially injurious substances such as chymotryptic enzyme. This property is due to mechanical obstruction rather than enzyme inhibition. Native vernix itself contains no detectable enzyme activity. A thin film of vernix in utero, therefore, may function to prevent loss of endogenous chymotrypsin from the underlying epidermis while preserving the microstructure of developing stratum corneum and protecting the epidermal barrier from noxious substances in the amniotic fluid. The multifunctionality of vernix supports the recommendation that vernix be left in place on the skin surface at birth.
